欧洲呼吸学会 2023 年大会亮点:慢性阻塞性肺病和严重哮喘

Eleanor Roberts
{"title":"欧洲呼吸学会 2023 年大会亮点:慢性阻塞性肺病和严重哮喘","authors":"Eleanor Roberts","doi":"10.33590/emjrespir/10303197","DOIUrl":null,"url":null,"abstract":"At the 2023 European Respiratory Society (ERS) International Congress, a significant part of the scientific discussion revolved around asthma and chronic obstructive pulmonary disease (COPD), with multiple abstracts and sessions dedicated to advances in targeted treatments, prevention, and care plans for these patient groups. Clinical remission was one of the key topics in the severe asthma (SA) sessions, with a focus on its definition, patient outcomes, and perceptions. Additionally, biological treatments, their affected pathways, and their role in helping patients achieve remission were central to these discussions. For COPD, much of the scientific dialogue centred around the updated Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, which classify patients according to the number of exacerbations, dyspnoea, and functional assessment, and suggest personalised treatment. Such treatments were the focus of numerous talks and posters, as evidence is mounting on the use of single inhaler triple therapy in patients with COPD and ≥2 moderate exacerbations or ≥1 leading to hospitalisation, with a positive impact on symptoms and quality of life (QoL). Exacerbation prevention was also a notable topic, as patients with COPD and asthma are more susceptible to infections, often leading to exacerbations, and are at higher risk of complications, hospitalisations, and death. Vaccination against vaccine-preventable diseases was recommended as a key cornerstone in the management of respiratory patients, and the importance of increasing awareness, access, and uptake of these vaccines was stressed.","PeriodicalId":300382,"journal":{"name":"EMJ Respiratory","volume":"26 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Highlights From the European Respiratory Society Congress 2023: Chronic Obstructive Pulmonary Disease and Severe Asthma\",\"authors\":\"Eleanor Roberts\",\"doi\":\"10.33590/emjrespir/10303197\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"At the 2023 European Respiratory Society (ERS) International Congress, a significant part of the scientific discussion revolved around asthma and chronic obstructive pulmonary disease (COPD), with multiple abstracts and sessions dedicated to advances in targeted treatments, prevention, and care plans for these patient groups. Clinical remission was one of the key topics in the severe asthma (SA) sessions, with a focus on its definition, patient outcomes, and perceptions. Additionally, biological treatments, their affected pathways, and their role in helping patients achieve remission were central to these discussions. For COPD, much of the scientific dialogue centred around the updated Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, which classify patients according to the number of exacerbations, dyspnoea, and functional assessment, and suggest personalised treatment. Such treatments were the focus of numerous talks and posters, as evidence is mounting on the use of single inhaler triple therapy in patients with COPD and ≥2 moderate exacerbations or ≥1 leading to hospitalisation, with a positive impact on symptoms and quality of life (QoL). Exacerbation prevention was also a notable topic, as patients with COPD and asthma are more susceptible to infections, often leading to exacerbations, and are at higher risk of complications, hospitalisations, and death. Vaccination against vaccine-preventable diseases was recommended as a key cornerstone in the management of respiratory patients, and the importance of increasing awareness, access, and uptake of these vaccines was stressed.\",\"PeriodicalId\":300382,\"journal\":{\"name\":\"EMJ Respiratory\",\"volume\":\"26 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EMJ Respiratory\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33590/emjrespir/10303197\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMJ Respiratory","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33590/emjrespir/10303197","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在 2023 年欧洲呼吸学会(ERS)国际大会上,围绕哮喘和慢性阻塞性肺病(COPD)的科学讨论占了很大一部分,多篇摘要和会议专门讨论了针对这些患者群体的靶向治疗、预防和护理计划的进展。临床缓解是重症哮喘(SA)会议的主要议题之一,重点关注其定义、患者疗效和看法。此外,生物治疗、其影响途径及其在帮助患者实现缓解方面的作用也是这些讨论的核心内容。关于慢性阻塞性肺疾病,大部分科学对话都围绕最新的慢性阻塞性肺疾病全球倡议(GOLD)指南展开,该指南根据病情加重次数、呼吸困难和功能评估对患者进行分类,并提出个性化治疗建议。此类治疗是众多演讲和海报的重点,因为越来越多的证据表明,对慢性阻塞性肺病且中度加重≥2次或≥1次导致住院的患者使用单吸入器三联疗法,对症状和生活质量(QoL)有积极影响。预防病情恶化也是一个值得注意的话题,因为慢性阻塞性肺病和哮喘患者更容易受到感染,这往往会导致病情恶化,并面临更高的并发症、住院和死亡风险。会议建议,接种疫苗预防可通过疫苗预防的疾病是管理呼吸系统疾病患者的关键基石,并强调了提高对这些疫苗的认识、获取和接种的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Highlights From the European Respiratory Society Congress 2023: Chronic Obstructive Pulmonary Disease and Severe Asthma
At the 2023 European Respiratory Society (ERS) International Congress, a significant part of the scientific discussion revolved around asthma and chronic obstructive pulmonary disease (COPD), with multiple abstracts and sessions dedicated to advances in targeted treatments, prevention, and care plans for these patient groups. Clinical remission was one of the key topics in the severe asthma (SA) sessions, with a focus on its definition, patient outcomes, and perceptions. Additionally, biological treatments, their affected pathways, and their role in helping patients achieve remission were central to these discussions. For COPD, much of the scientific dialogue centred around the updated Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, which classify patients according to the number of exacerbations, dyspnoea, and functional assessment, and suggest personalised treatment. Such treatments were the focus of numerous talks and posters, as evidence is mounting on the use of single inhaler triple therapy in patients with COPD and ≥2 moderate exacerbations or ≥1 leading to hospitalisation, with a positive impact on symptoms and quality of life (QoL). Exacerbation prevention was also a notable topic, as patients with COPD and asthma are more susceptible to infections, often leading to exacerbations, and are at higher risk of complications, hospitalisations, and death. Vaccination against vaccine-preventable diseases was recommended as a key cornerstone in the management of respiratory patients, and the importance of increasing awareness, access, and uptake of these vaccines was stressed.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信